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Background: Macular hole results from a tractional force at the vitreo-retinal interface which is developed by
modification and subsequent degeneration of the posterior precortical vitreous and the internal limiting membrane
(ILM). Meanwhile, the wet type of age-related macular degeneration (AMD) is caused by the submacular formation of
choroidal neovascularization (CNV). Although exudative changes derived from CNV may cause epiretinal membrane
(ERM) formation, which can also cause tractional force at the vitreo-retinal interface, there have been few reports of
AMD-associated macular hole development in which the full thickness of the retinal tissue is completely torn by the
tractional force. Moreover, intraoperative finding of macular hole associated with AMD with a possible involvement of
subretinal lesion has not been described.
Case presentation: A 78-year-old man diagnosed with wet AMD with subretinal fluid and mild cataract received 8
treatments with intravitreal pegaptanib. After AMD remission, he developed a secondary macular hole in the same eye.
He underwent a pars plana vitrectomy that successfully closed the macular hole. Intraoperatively, it was found that the
patient’s vitreous was formed and that the ERM and ILM were adherent, suggesting the involvement of a tractional
force at the vitreo-retinal interface due to an inflammatory reaction related to AMD and/or intravitreally injected chemical
compounds, resulting in macular hole development. Changes in the condition of his AMD and the RPE were observed
on a fluorescein angiogram (FA) and an indocyanine green angiogram (IA) that preceded macular hole development,
suggesting that subretinal changes may also have been involved in the pathogenesis.
Conclusion: These clinical data, including the intraoperative findings and the temporal changes in the angiograms,
suggest that an inflammatory reaction at the vitreo-retinal interface and subretinal lesion related to AMD contribute to
the macular hole development in AMD patients treated with intravitreal injection.
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The understanding of macular hole development has been
advanced by the knowledge of posterior precortical vitreous
pocket formation [1] and recently published studies on
surgical findings [2-6]. The tractional force generated at the
vitreo-retinal interface is the main factor in macular hole
pathogenesis; removal of the internal limiting membrane
(ILM) and posterior vitreous, which often exhibits patho-
logical changes, is now a well-accepted surgical approach.
Age-related macular degeneration (AMD) is a leading
cause of blindness [7,8], although recent progress in anti-
vascular endothelial growth factor (anti-VEGF) therapy
has substantially improved the visual prognosis of one
AMD subtype, namely, wet AMD [9-11]. The exudative
change in choroidal neovascularization (CNV) can cause
pigment epithelial detachment (PED), exudative retinal
detachment, and macular edema, whereas contraction of
CNV with or without treatment may cause a retinal
pigment epithelial (RPE) tear [12]. The exudative change
can also cause secondary epiretinal membrane (ERM)
formation as a result of a modification of the vitreo-retinal
interface [13]. However, macular hole development, which
is another disease related to the vitreo-retinal tractional
force associated with CNV, is rarely reported. In a macular
hole, the tractional force completely tears the full
thickness of the retinal tissue. In this report, the clinical
course of an AMD case with a macular hole is described.
Case presentation
In August 2009, a 78-year-old man presented with impaired
central vision in his right eye and was diagnosed with wetFigure 1 Macular findings during AMD treatment. (A) A fundus photog
region (arrowheads). (B) A FA obtained prior to the initial intravitreal inject
(arrows). (C) An IA obtained prior to the initial intravitreal injection support
prior to the initial intravitreal injection showed subretinal fluid. (E) An OCT
Mild ERM formation and mild vitreo-retinal traction were observed at the fAMD accompanied by subretinal fluid (Figure 1A-D) and
mild cataract at the Medical Retina Division Clinic
(AMD Clinic) of the Department of Ophthalmology, Keio
University Hospital (Tokyo, Japan). His best corrected
visual acuity (BCVA) was 0.7 in decimal VA (0.155 in
logMAR). He had received eight intravitreal injections of
pegaptanib by January 2011, which resolved the exudative
changes and improved his BCVA to 1.2 (−0.079). At this
time, he had mild ERM formation and mild vitreo-retinal
traction at the fovea (Figure 1E), which were not found at
his first visit.
After remission of his exudative change, he suspended
his visits to the AMD clinic. However, 2 years later, in
February 2013, he had a sudden, substantial impairment
of visual acuity. His BCVA was reduced to 0.2 (0.699),
which was determined to be due to the formation of a
macular hole (Figure 2A-D). A fluorescein angiogram
(FA) and an indocyanine green angiogram (IA) showed
that the CNV still existed, and the hyperfluorescent
area in the FA expanded toward halfway around the
fovea (Figure 2B) which may have included atrophic
change in the RPE.
In May 2013, he underwent pars plana vitrectomy
with gas tamponade (20% SF6) and cataract surgery.
Intraoperative findings revealed that he had a formed
vitreous despite repeated intravitreal injections. Posterior
vitreous detachment (PVD) was only observed at the optic
disc, and complete PVD was accomplished during the
vitrectomy. His posterior hyaloid cortex was thickened,
the ERM was sticky (Figure 2E), and the ILM was
markedly adherent. The macular hole was retracted andraph at his first visit. Subretinal fluid was observed in the macular
ion revealed leakage from the CNV of occult with no classic-type
ed this finding showing the CNV (arrowheads). (D) An OCT image
image at the time of AMD remission after 8 pegaptanib injections.
ovea.
Figure 2 Macular findings after macular hole formation. (A) A fundus photograph at the time of macular hole diagnosis. (B) A FA obtained
after the diagnosis of the macular hole showed enlargement of the hyperfluorescent area (arrows). (C) An IA obtained after the diagnosis of the
macular hole showed the CNV (arrowheads). (D) An OCT image of the macular hole showing an irregularity of the RPE/Bruch complex. (E) The
intraoperative discovery of an adherent ERM. The macular hole was retracted and distorted by ERM peeling. (F) An OCT image after surgery, showing a
disrupted photoreceptor cell layer, the ellipsoid zone, and an irregularity of the RPE/Bruch complex after macular hole closure. (G) A fundus photograph
obtained after macular hole closure. (H) Hyperfluorescent area in a FA was clearly observed post-operatively (arrows) after the vitrectomy and the cataract
extraction. (I) An IA showed that the CNV remained after macular hole surgery and its closure (arrows).
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macular hole had closed and his BCVA had improved to
0.4 (0.398) (Figure 2F,G).
The CNV tissue together with the RPE change second-
arily caused by the CNV lesion surrounding the fovea
remained post-operatively, as demonstrated by a FA and
an IA (Figure 2H,I). The FA image was more clearly
recorded post-operatively than pre-operatively (Figure 2B),
most likely because of the cataract extraction. Although
the macular hole was closed, defects in the ellipsoid zone,
which has been called the inner segment/outer segment
(IS/OS) line, and irregularities in the photoreceptor layer
together with RPE were observed on optical coherence
tomography (OCT) (Figure 2F).
Discussion
There have been no other reports of intraoperative findings
of a macular hole developing secondary to wet AMD.
Despite several intravitreal injections, the patient’s vitreous
was not liquefied. The intraoperative findings included
adherent ERM and ILM, which suggested the influence of
inflammatory reactions related to the exudative changes
of AMD at the vitreo-retinal interface [14]. Moreover,
intravitreal injections of a drug can cause intraocularinflammation [11,15]. The properties of anti-VEGF and its
diluents or other included compounds could have also
been involved in the inflammatory reaction that caused
the modifications of the vitreo-retinal interface. Moreover,
the subretinal condition due to AMD preceded macular
hole development, suggesting that the pathological RPE
may have induced retinal vulnerability, and the CNV
might have contracted and accelerated the tangential
traction from the subretinal side, and both of which may
have possibly contributed to macular hole development.
Although the macular hole was closed, the photorecep-
tor layer remained disorganized. This disorganization may
have resulted because the RPE was in a pathological state
due to the AMD and could not induce proper recovery
processes during the macular hole closure. The surrounding
microenvironment, including the RPE, is important for the
proper healing of a macular hole.
One case of macular hole development with AMD
after a single injection of intravitreal ranibizumab has been
previously reported [16]. In that case, vitreo-macular
traction syndrome was observed before treatment and
progressed after the injection. However, in the case
presented here, there are multiple possibilities for the
underlying mechanism of the macular hole development,
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tion including CNV and the RPE, the chronic progression
of vitreous modifications due to exudative changes caused
by AMD, and intravitreal injections, which cause a sticky
ERM and ILM changes.
Conclusion
These clinical data, including the intraoperative findings
and the temporal changes related to AMD, suggest that
an inflammatory reaction at the vitreo-retinal interface
and subretinal pathological changes contribute to retinal
conditions in AMD cases that are treated with intravitreal
injections.
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